The Cork Cancer Research Centre acts as a foundation upon which inter-disciplinary research programmes are built. We have initiated, and continue to encourage, the interaction of scientists and clinicians with complementary skills.
Reaping the rewards of these collaborations, our co-operative efforts have made significantly more progress than was thought possible at our launch in 1999.
Our objective is to build upon this impetus. Meaningful contribution to the development of novel anti-cancer treatments continues to be our ambition and it is important that the direction of our research remains applied. Thus we will not become emotionally removed from those afflicted by cancer and ensure it is the patients and families who will benefit from our research endeavours.
HHMI is a science philanthropy whose mission is to advance biomedical research and science education for the benefit of humanity. We empower exceptional scientists and students to pursue fundamental questions about living systems. Headquartered in Chevy Chase, MD, HHMI employs more than 3,000 individuals across the United States. In fiscal year 2012, HHMI invested $695 million in U.S. research and provided $78 million in grants and other support for science education.
The J. Craig Venter Institute was formed in October 2006 through the merger of several affiliated and legacy organizations — The Institute for Genomic Research (TIGR) and The Center for the Advancement of Genomics (TCAG), The J. Craig Venter Science Foundation, The Joint Technology Center, and the Institute for Biological Energy Alternatives (IBEA). Today all these organizations have become one large multidisciplinary genomic-focused organization. With more than 300 scientists and staff, more than 250,000 square feet of laboratory space, and locations in Rockville, Maryland and San Diego, California, the new JCVI is a world leader in genomic research.
Affiliated with Université de Montréal, the MHI is the flagship of cardiovascular medicine in Quebec, a recognized research leader in Canada and around the world, and a true spearhead in cutting-edge cardiovascular medicine.
One of the features that make the Research Centre stand out is the balance and strong synergy between clinical and basic research. This strength, which dates back to the founding of the MHI, not only sets the MHI and its Research Centre apart, it has also historically been the foundation and vehicle for the timely, organized and professional translation of discoveries into medical practice for the great benefit of patients at the MHI and around the world.
The General Clinical Research Center (GCRC) at LA BioMed has been continuously funded since 1968 and supports the multidisciplinary research of a large cadre of well-funded and productive investigators. Their publication rate is one of the highest among GCRCs nationwide. In 2002, the outpatient clinical research unit opened an additional 5,500 square feet for research, with an adjoining 2,000-square-foot conference room for research education-related activities. Several Harbor-UCLA research centers have their administrative home at LA BioMed, creating an expanded support base for promoting clinical and translational research. Current centers include the Emerging Infection Center, Perinatal Research Center, Cancer Prevention Clinical Trials Center, Liu Center for Pulmonary Hypertension Research, Rehabilitation Clinical Trials Center, CT Reading Center, HIV Medicine Research Center, UCLA Center for Vaccine Research, and Male Reproductive Center, which is a World Health Organization-collaborating Center for Research in Reproduction and a National Institute of Child Health and Human Development-funded Contraceptive Clinical Trial Network Center (male area).
The total clinical research space available at LA BioMed is 25,000 square feet. The institute recently acquired major equipment (e.g., real-time PCR, laser capture microdissector, liquid chromatography-tandem mass spectrometry [LS-MSMS], matrix-assisted laser desorption/ionization-time-off light [MALDI-TOF] mass spectrometer) for scientific and technical support of LA BioMed investigators. Since 1998, LA BioMed, in partnership with California State University Dominguez Hills, has trained underrepresented students in biomedical research. These National Institute of General Medical Sciences-funded programs pair underrepresented undergraduate and master’s-level students in biology with well-funded mentors at Harbor-LA BioMed. Many of these students have since applied and been admitted to PhD programs throughout the country.
Since its founding in 1947, Dana-Farber has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow’s cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.
Our research at the Wellcome Trust Sanger Institute builds understanding of gene function in health and disease as well as creating resources of lasting value to biomedical research.
We study diseases that have an impact on health globally by investigating genomes. Building on our past achievements and based on priorities that exploit the unique expertise of our Faculty of researchers, we will lead global efforts to understand the biology of genomes. We are convinced of the importance of making this research available and accessible for all audiences.
The Eli and Edythe L. Broad Institute of Harvard and MIT is founded on two core beliefs:
This generation has a historic opportunity and responsibility to transform medicine by using systematic approaches in the biological sciences to dramatically accelerate the understanding and treatment of disease.
To fulfill this mission, we need new kinds of research institutions, with a deeply collaborative spirit across disciplines and organizations, and having the capacity to tackle ambitious challenges.
Whitehead Institute is a world-renowned non-profit research institution dedicated to improving human health through basic biomedical research. By cultivating a deeply collaborative culture and enabling the pursuit of bold, creative inquiry, Whitehead fosters paradigm-shifting scientific achievement. For more than 30 years, Whitehead faculty have delivered breakthroughs that have transformed our understanding of biology and accelerated development of therapies for such diseases as Alzheimer’s, Parkinson’s, diabetes, and certain cancers.
The mission of The George Institute for Global Health is to improve the health of millions of people worldwide. With projects in more than 50 countries, we have raised a quarter of a billion dollars for global health research in the last decade and we have been ranked among the top 10 research institutions in the world for scientific impact by the SCImago Institution Rankings World Report in 2011 – 2013.
The Australian Regenerative Medicine Institute is a $153 million medical research centre that officially opened in April 2009. It is based at the Monash University Clayton campus.
Established through a joint venture between Monash University and the Victorian Government, ARMI builds on the University’s existing strengths in biomedical research and supports the critical infrastructure required to deliver the next generation of discoveries in regenerative medicine.
At full capacity ARMI will be one of the world’s largest regenerative medicine and stem cell research centres. Its scientists focus on unraveling the basic mechanisms of the regenerative process, aiming to eventually enable doctors to prevent, halt and reverse damage to vital organs due to disease, injury or genetic conditions.
This work will form the basis of treatments for conditions such as neurodegenerative disorders, diabetes, arthritis, musculo-skeletal and cardiovascular diseases.
The Center of Molecular Immunology (CIM) is a Cuban biotechnology institution devoted to basic research, development and manufacturing of products from mammalian cell culture according to the regulations of the current Good Manufacturing Practices (cGMP).
CIM is a high technology company which is part of the Biotechnology and Pharmaceutical Industries Organization, BIOCUBAFARMA.
CIM have a wide experience in the field of monoclonal antibodies, in which has been working since 1980.
The year 2013 began with 1.127 workers and four plants for biological products, EPOVAC for the manufacturing of recombinant proteins, ANTYTER for the production of recombinant monoclonal antibodies, LABEX for manufacturing biological reagents for in vitro use and Pharmaceutical Biotech Co. Ltd (BPL), a high-tech Chinese-Cuban joint venture, located in the Economic Technological Development Area in Beijing, dedicated to the production of monoclonal antibodies.
CIM´s mission is research, development; scale up manufacturing and marketing of biopharmaceuticals, domestically and internationally, especially monoclonal antibodies and other recombinant proteins for the diagnosis and treatment of cancer and other immune system-related diseases and the negotiation of intangibles in Cuba and abroad.
It´s vision is to achieve global impact in the treatment of cancer and other chronic non-transmissible diseases with innovative products; developing a sustainable export growth, accessing the markets of industrialized countries. To become a leading international biotechnology company developing a corporate culture based on excellence, innovation, diversification, and dedication to work.
Concern Worldwide works with the world’s poorest people to transform their lives.
We are an international humanitarian organisation dedicated to tackling poverty and suffering in the world’s poorest countries.
We work in partnership with the very poorest people in these countries, directly enabling them to improve their lives, as well as using our knowledge and experience to influence decisions made at a local, national and international level that can significantly reduce extreme poverty.
The Mater Foundation was established in 1985 as the official fundraising body of The Mater Misericordiae University Hospital.
It exists to inspire and enable financial support from the community for exceptional patient care at The Mater Misericordiae University Hospital.
Funds raised through the Mater Foundation are used to purchase state-of-the-art equipment, enhance facilities and to ensure that all patients at the hospital are cared for in a restful, healing and comfortable environment.
Working closely with healthcare professionals, hospital management, our donors and volunteers, the Mater Foundation makes possible the investment of the community in its own healthcare.
St. James’s Hospital Foundation (the Foundation) processes and disburses donations received by St. James’s Hospital and fundraises for the hospital. All privately given funds are used to buy equipment, enhance the amenities and environment of the hospital and provide for staff education and research – all aimed at providing world-class care for the maximum number of patients.
While being resourced by the hospital, the Foundation is established as a separate legal entity to the hospital to ensure the integrity of its operations and in particular its financial operations.
The mission or purpose of Spina Bifida Hydrocephalus Ireland is to provide information, support and advice to people with Spina Bifida and/or Hydrocephalus, their parents and carers, as well as to promote social inclusion and equality for people with Spina Bifida and/or Hydrocephalus in Irish society.
The SUPPORT ORGANISATION FOR TRISOMY (S.O.F.T.) was founded in Ireland in 1991 as a voluntary group dedicated to providing support for families of children born with the chromosomal disorders – Patau’s Syndrome or Trisomy l3 and Edwards’ Syndrome or Trisomy 18.
One in four of all pregnancies ends in miscarriage and a high proportion are thought to be caused by a chromosomal disorder. A high proportion of trisomy 13 and trisomy 18 pregnancies end in miscarriage within twelve weeks of conception. It is therefore quite rare for such a pregnancy to continue to full term. The incidence of trisomy 13 is about 1 in 5,000 of total births while that of trisomy 18 is about 1 in 2,500 of total births.
Support is provided during prenatal diagnosis, during the child’s life and after the child’s passing.
SOFT puts families in contact with one another, provides information, funds bereavement counselling, funds respite assistance, publishes the SOFT booklet Why Our Baby and a newsletter, organises conferences and arranges professional speakers, do fundraising through various events and links with S.O.F.T. organisations worldwide.
Babies have been born with Trisomy 13 and 18 since the beginning of time, but it was only in 1960 that Dr. Patau and Dr. Edwards identified the respective features of the syndromes. Both syndromes are the result of an extra 13th or 18th chromosome respectively being present in each cell in the body. Different variants of these syndroms also exist, but are less common.
Sightsavers works to combat blindness in developing countries, restoring sight through specialist treatment and eye care. We also support people who are irreversibly blind by providing education, counselling and training. We help the people who need it most – those living in poverty in some of the world’s poorest countries.
To empower African eye surgeons to stay in Africa and work towards eradicating needless blindness.
Through advocacy, research and targeted treatment programmes Right to Sight develop sustainable local expertise in high volume, affordable eye care services.
To eliminate needless blindness in Africa by securing a sustainable supply of African eye surgeons and providing easily accessible, affordable eye care to all.
Established in 2003, Plan Ireland is a child-centered community development organisation, part of Plan International which itself was founded over 75 years ago. It is an independent organisation with no religious, political or governmental affiliations.
Plan is one of the oldest and largest international development agencies in the world. It currently works in 50 developing countries across Africa, Asia and the Americas directly supporting more than 1,500,000 children and their families, and an estimated 9,000,000 others living in communities working with Plan.
Plan Ireland receives tremendous support from the Irish public, over 8,500 of whom sponsor children.
To improve diagnosis and education of ovarian cancer within Ireland, through sharing global research and best practice, and providing support and advocacy through OvaCare’s dedicated support network.